Oruka Therapeutics (ORKA) financial statements
Net income was -$105M.
Free cash flow was -$88M.
The diluted share count rose 129% over the period (dilution).
Income statement
Fiscal years, from Oruka Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | — |
| Research and development | $7M | $12M | $14M | $4M | $2M | $5M | $14M | $5M | $1M | $101M |
| Selling, general and admin | $4M | $4M | $5M | $4M | $4M | $5M | $6M | $6M | $6M | $21M |
| Operating income | -$11M | -$17M | -$19M | -$8M | -$6M | -$10M | -$19M | -$11M | -$7M | -$122M |
| Interest expense | $4,000 | — | $6,000 | $8,000 | $7,000 | $9,000 | — | — | — | — |
| Pre-tax income | — | -$16M | -$19M | -$8M | -$6M | -$10M | -$19M | — | — | -$105M |
| Income tax | $0 | $0 | -$61,000 | -$31,000 | -$167,000 | -$9,000 | $0 | $0 | $0 | — |
| Net income | -$11M | -$16M | -$18M | -$8M | -$5M | -$10M | -$19M | -$10M | -$5M | -$105M |
| EPS (diluted) | -$1.82 | -$1.81 | -$1.77 | -$10.31 | -$4.15 | -$2.07 | -$1.39 | -$0.69 | -$0.37 | — |
| Diluted shares | 6M | 9M | 10M | 1M | 1M | 5M | 14M | 14M | 14M | — |
Balance sheet
Fiscal years, from Oruka Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and short-term investments | $39M | $21M | $12M | $7M | $8M | $49M | $53M | $42M | $37M | $337M |
| Total current assets | $39M | $21M | $12M | $7M | $8M | $50M | $54M | $43M | $38M | $344M |
| Property, plant and equipment | $28,000 | $66,000 | $42,000 | $24,000 | $10,000 | $21,000 | $48,000 | $25,000 | $10,000 | $288,000 |
| Total assets | $40M | $25M | $12M | $7M | $9M | $50M | $55M | $43M | $38M | $489M |
| Total current liabilities | $2M | $2M | $2M | $793,000 | $926,000 | $3M | $3M | $1M | $637,000 | $15M |
| Total liabilities | $2M | $2M | $2M | $793,000 | $926,000 | $4M | $4M | $1M | $841,000 | $17M |
| Shareholders' equity | $38M | $22M | $10M | $6M | $8M | $47M | $51M | $42M | $37M | $472M |
| Net debt | -$39M | -$7M | -$9M | -$7M | -$8M | -$49M | -$53M | -$42M | -$37M | -$47M |
Cash flow
Fiscal years, from Oruka Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$11M | -$15M | -$17M | -$8M | -$5M | -$8M | -$19M | -$11M | -$5M | -$88M |
| Capital spending | $11,000 | $12,000 | $3,000 | $4,000 | $4,000 | $19,000 | $43,000 | $2,000 | $0 | $209,000 |
| Free cash flow | -$11M | -$15M | -$17M | -$8M | -$5M | -$8M | -$19M | -$11M | -$5M | -$88M |
| Stock-based compensation | $599,000 | $576,000 | $458,000 | $273,000 | $151,000 | $43,000 | $497,000 | $556,000 | $686,000 | $24M |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for ORKA.
Open ORKA in InvestinglyQuestions
How much free cash flow does Oruka Therapeutics generate?
-$88M in fiscal 2025 (operating cash flow minus capital spending).
From Oruka Therapeutics's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.